Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (2 quarters reported)
$507M in Q4 2015 → $585M now. Hover for any quarter.
As reported for the quarter ended June 30, 2016. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Seres Therapeutics Inc | 63.0% | Trimmed 9.9% | 12,682,876 | $368M |
| Editas Medicine Inc | 20.7% | New | 4,955,316 | $121M |
| Syros Pharmaceuticals Inc | 14.9% | New | 4,806,656 | $87.2M |
| T2 Biosystems Inc | 1.0% | Unchanged | 741,755 | $5.85M |
| EB Eleven Biotherapeutics Inc | 0.4% | Unchanged | 1,466,417 | $2.46M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 1 quarters.
quarter ended June 30, 2016 · filed August 15, 2016
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Editas Medicine Inc | New | +4,955,316 | +$121M | 20.7% |
| Syros Pharmaceuticals Inc | New | +4,806,656 | +$87.2M | 14.9% |
| Seres Therapeutics Inc | Trimmed | −1,400,703 | −$40.7M | 63.0% |
Loading...
